Rising focus on genomics over the past few years, coupled with the advancements in the field of molecular biology, has played an instrumental role in early diagnosis followed by the effective treatment of various diseases. The paradigm shift toward specific treatment along with the growing adoption of precision medicine has escalated the demand for genomic-based medicine by various end users. The incorporation of clinical biomarkers in breast cancer diagnostics aids in the identification of different biomarkers associated with the tumor grade and different cancer subtypes, which specifically reflects an individual’s health status accompanies and risk associated with breast cancer. The use of biomarker-based tests for identification of prognosis and recurrence of breast cancer has high predictive accuracy, minimally invasive, reproducible, and measurable, and is also widely accepted by the physicians and patients. In addition to this, breast cancer diagnostics based on clinical biomarkers have been extensively used for the evaluation of potential drug therapies. With the advancements in the field of biochemistry and medicine followed by omics, the clinical biomarkers appear to hold great potential for transforming medical practices into personalized medicine.

1. Product Definition 

2. Market Scope 

3. Research Methodology 

4. Market Overview 

5. Next-Generation Breast Cancer Diagnostics and Screening Market Dynamics

6. Competitive Landscape 

7. Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), 2019-2030 

8. Next-Generation Breast Cancer Diagnostics and Screening Market (by Cancer Subtype) 2019-2030 

9. Next-Generation Breast Cancer Diagnostics and Screening Market (by Test Type) 2019-2030 

10. Next-Generation Breast Cancer Diagnostic and Screening Market (by Region) 2019-2030

11. Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), 2019-2030 

12. Company Profiles